Drug Profile
Research programme: dual adenosine A2A/A1 receptor antagonists - Johnson & Johnson
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Johnson & Johnson
- Class 3-ring heterocyclic compounds; Indenes; Pyrimidines; Small molecules
- Mechanism of Action Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (PO)
- 26 Aug 2010 Preclinical trials in Parkinson's disease in USA (PO)
- 26 Aug 2010 Pharmacodynamics data from preclinical trials presented at the 240th National Meeting of the American Chemical Society (ACS-2010)